Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» solid tumors
solid tumors
Novartis Culls 10% of Pipeline, Doubles Down on Five Core Therapeutic Areas
BioSpace
Wed, 04/26/23 - 10:24 am
Novartis
earnings
solid tumors
hematology
immunology
Neuroscience
cardiovascular disease
Roche, seeing MAGE magic wane, makes pair of solid tumor bispecifics disappear
Fierce Biotech
Wed, 04/26/23 - 10:08 am
Roche
earnings
solid tumors
MAGE-A4
FDA clears Sensei’s IND to start Phase I/II therapy trial of SNS-101
Clinical Trials Arena
Fri, 04/21/23 - 10:04 am
Sensei Biotherapeutics
SNS-101
clinical trials
solid tumors
BMS signs ADC development deal with Munich-based biotech worth more than $1B
Medical Marketing and Media
Thu, 04/20/23 - 12:00 pm
Bristol Myers Squibb
Tubulius
cancer
solid tumors
antibody-drug conjugate
In a refreshingly transparent disclosure, NGM Bio CEO reveals what led to 33% head count reduction
Fierce Biotech
Wed, 04/5/23 - 11:58 am
NGM Biopharmaceuticals
solid tumors
layoffs
BioNTech Adds Two ADCs in Second Deal in as Many Months
BioSpace
Mon, 04/3/23 - 10:44 pm
BioNTech
antibody-drug conjugate
solid tumors
Duality Biologics
Positive topline data for Bolt’s BDC-1001 in HER2 solid tumours
Clinical Trials Arena
Fri, 03/31/23 - 10:22 am
Bolt Biotherapeutics
BDC-1001
solid tumors
Roche
Bristol Myers Squibb
FDA grants full approval to Keytruda in tumor-agnostic setting
Endpoints
Thu, 03/30/23 - 10:59 pm
Merck
Keytruda
tumor agnostic
solid tumors
With one of biotech's largest private rounds in a year, ArriVent enters PhIII
Endpoints
Mon, 03/27/23 - 11:25 am
ArriVent Biopharma
funding
solid tumors
23andMe doses first patient in ph2a anti-tumour monotherapy
Pharmaphorum
Wed, 03/1/23 - 09:48 am
23andMe
clinical trials
solid tumors
23ME-00610
Months after going public, Apexigen lays of 55% of staff and considers exit routes
Fierce Biotech
Mon, 02/27/23 - 10:05 am
Apexigen
Epitomics
layoffs
solid tumors
sotigalimab
FDA hands down a partial hold for PhI/II trial of Blueprint’s CDK2 inhibitor
Endpoints
Fri, 02/10/23 - 11:05 am
FDA
Blueprint Medicine
clinical trials
solid tumors
BLU-222
Merck and Nectin to Study Novel Anti-PVR Candidate with Keytruda
BioSpace
Tue, 02/7/23 - 12:15 pm
Merck
Nectin Therapeutics
NTX1088
solid tumors
BMS returns $475M IL-12 oncology asset to Dragonfly’s pond
Fierce Biotech
Mon, 02/6/23 - 06:12 pm
Dragonfly Therapeutics
Bristol Myers Squibb
oncology
DF6002
solid tumors
J&J quietly punts a pair of early-stage bispecifics for solid tumors
Endpoints
Thu, 01/26/23 - 10:45 am
JNJ
bispecific antibodies
solid tumors
Is mesothelin a key to tackling solid tumors? Some biotech companies are betting that it is
Stat
Sun, 01/22/23 - 01:05 pm
cancer
oncology
mesothelin
solid tumors
AbbVie inks Immunome solid tumor deal that could top $2.8B in biobucks
Fierce Biotech
Sun, 01/8/23 - 10:07 pm
AbbVie
Immunome
biobucks
solid tumors
Sanofi expands on Innate tumor collab with fresh $1.44B deal for more NK engagers
Fierce Biotech
Mon, 12/19/22 - 11:19 am
Sanofi
Innate Pharma
natural killer cells
solid tumors
Nectin's Series A Hits $25M as Investors Support New Target for Solid Tumors
BioSpace
Wed, 11/30/22 - 10:56 am
Nectin Therapeutics
funding
solid tumors
CatalYm Closes EUR 50 Million Series C Financing to Expand and Accelerate Phase 2 Clinical Development of Visugromab in Patients with Solid Tumors
BioSpace
Tue, 11/22/22 - 11:03 am
CatalYm
funding
visugromab
solid tumors
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
…
next ›
last »